Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yukihito Ishizaka is active.

Publication


Featured researches published by Yukihito Ishizaka.


Biochemical and Biophysical Research Communications | 1988

Expression of proto-ret mRNA in embryonic and adult rat tissues

Tomoko Tahira; Yukihito Ishizaka; Takashi Sugimura; Minako Nagao

The expression of proto-ret mRNA in adult and embryonic rat tissues were studied. Very low levels of proto-ret transcripts were found in adult rat tissues such as brain, thymus and testis. The sizes of these transcripts were almost the same as those found in human neuroblastoma, SK-N-SH cells. High levels of proto-ret transcripts were found in the rat conceptus on days 9 to 11 of gestation, but not at later stages of development. The level of transcripts in the conceptus on day 10 was about 20-50 times that in adult rat thymus. These results suggest that the proto-ret product, which is possibly a receptor-type tyrosine kinase, has special functions during embryonic development.


Human Gene Therapy | 2000

Improved Gene Transfer to Neuroblastoma Cells by a Monoclonal Antibody Targeting RET, a Receptor Tyrosine Kinase

Lisa Yano; Mari Shimura; Mika Taniguchi; Yasuhide Hayashi; Toshimitsu Suzuki; Kiyohiko Hatake; Fumimaro Takaku; Yukihito Ishizaka

Receptor-mediated gene transfer is an effective strategy among nonviral vector systems. It is, however, crucial to develop various types of monoclonal antibodies satisfying both the binding specificity for cell targeting and the capacity of endocytosis required for gene transfer. In the present study, we generated a novel monoclonal antibody (NBL-1) to RET, a receptor tyrosine kinase expressed in both neuroblastoma cells and cells present in substantia nigra, a responsive locus of Parkinsons disease. NBL-1, when added to the culture medium of the neuroblastoma cells, was incorporated by endocytosis in a wortmannin-sensitive manner. Using a biotinylated NBL-1 complexed with plasmid DNAs based on electrostatic interaction through avidin-conjugated polylysines, exogenous luciferase genes were expressed in neuroblastoma cells at a more than 10-fold higher level. The expression level of the gene based on NBL-1 was comparable to that obtained by a geneporter system, an improved nonviral gene transduction method. Furthermore, the NBL-1-based gene transfer mediated the formation of more than 20-fold higher numbers of drug-resistant colonies. In contrast, RET-negative cells, which included HeLa, HT1080, Caco-2, and Colo205 cells, did not show any increased expression of an exogenous gene by NBL-1. These data suggest that the RET molecules enable selective gene transduction, and that NBL-1 may possibly be applied to gene therapy for neuroblastomas and Parkinsons disease.


Leukemia | 2000

Induction of apoptosis in human hematopoietic U937 cells by granulocyte–macrophage colony-stimulating factor: possible existence of caspase 3-like pathway

E Okuma; Kumiko Saeki; Mari Shimura; Yukihito Ishizaka; E Yasugi; Akira Yuo

Granulocyte–macrophage colony-stimulating factor (GM-CSF) induced apoptosis in human hematopoietic U937 cells by itself and in a synergistic manner with tumor necrosis factor (TNF). GM-CSF-induced apoptosis was not inhibited by caspase inhibitors YVAD-CMK, DEVD-CHO and z-VAD-FMK, under the condition that these inhibitors potently suppressed TNF-induced apoptosis. Both GM-CSF and TNF induced caspase 3-like activity in this cell line though the time course was distinct between two cytokines, and combined stimulation of cells with GM-CSF plus TNF induced additive or synergistic activation of caspase 3-like activity. Amount of immunoreactive cleaved forms of caspase 3 recognized by specific antibody was completely dissociated with its enzymatic activity when the cells were stimulated with GM-CSF, but not with TNF. These results indicate that GM-CSF induces apoptosis of U937 cells via unknown pathway, which seems to be mediated by caspase 3-like activity, yet not caspase 3 itself, resistant to the caspase inhibitors, and synergistically interacts with conventional caspase 3 pathway of TNF. Possible involvement of caspases 1 and 8 (-like activity) but not caspase 7 in this pathway was also suggested.


Archives of Biochemistry and Biophysics | 2003

Loss of p53 induces M-phase retardation following G2 DNA damage checkpoint abrogation

Yuzuru Minemoto; Sanae Uchida; Motoaki Ohtsubo; Mari Shimura; Toshiyuki Sasagawa; Masato Hirata; Hitoshi Nakagama; Yukihito Ishizaka; Katsumi Yamashita

Most cell lines that lack functional p53 protein are arrested in the G2 phase of the cell cycle due to DNA damage. When the G2 checkpoint is abrogated, these cells are forced into mitotic catastrophe. A549 lung adenocarcinoma cells, in which p53 was eliminated with the HPV16 E6 gene, exhibited efficient arrest in the G2 phase when treated with adriamycin. Administration of caffeine to G2-arrested cells induced a drastic change in cell phenotype, the nature of which depended on the status of p53. Flow cytometric and microscopic observations revealed that cells that either contained or lacked p53 resumed their cell cycles and entered mitosis upon caffeine treatment. However, transit to the M phase was slower in p53-negative cells than in p53-positive cells. Consistent with these observations, CDK1 activity was maintained at high levels, along with stable cyclin B1, in p53-negative cells. The addition of butyrolactone I, which is an inhibitor of CDK1 and CDK2, to the p53-negative cells reduced the floating round cell population and induced the disappearance of cyclin B1. These results suggest a relationship between the p53 pathway and the ubiquitin-mediated degradation of mitotic cyclins and possible cross-talk between the G2-DNA damage checkpoint and the mitotic checkpoint.


Gene | 1994

Cloning and activation of the Syrian hamster neu proto-oncogene

Takuro Nakamura; Toshikazu Ushijima; Yukihito Ishizaka; Minako Nagao; Masami Aral; Yukari Yamazaki; Takatoshi Ishikawa

Point mutations of the Syrian hamster neu proto-oncogene have been observed in the transmembrane domain of N-nitroso-N-ethylurea (ENU)-induced neurofibromas. Genomic DNA derived from tumor tissue showed transforming activity in an NIH 3T3 assay and a cDNA clone of the hamster neu gene, containing the entire protein-coding region, was isolated from a transformant cDNA library. The encoded product is 92 and 88% homologous to the rat neu and the human c-erbB-2, respectively. The product of the mutated hamster neu gene showed increased autophosphorylation of Tyr residues.


Journal of Cellular Physiology | 2002

New human myelodysplastic cell line, TER‐3: G‐CSF specific downregulation of Ca2+/calmodulin‐dependent protein kinase IV

Yuji Mishima; Yasuhito Terui; Yuko Mishima; Misa Katsuyama; Masaki Mori; Hiroshi Tomizuka; Toshiyuki Takizawa; Akira Miyazato; Masuzu Ueda; Muneo Yamada; Hirotoshi Hayasawa; Nobuyuki Mizunuma; Yukihito Ishizaka; Kazuma Ikeda; Takashi Kato; Keiya Ozawa; Kiyohiko Hatake

We have established a new hematopoietic cell line from a patient with myelodysplastic syndrome (MDS), which was refractory anemia with excess blasts (RAEB). This cell line, designated TER‐3, depends on several cytokines for long‐term survival and growth, and requires interleukin‐3 (IL‐3) for continuous growth. Cytochemical analysis revealed that TER‐3 cells are weakly dianisidine positive and nonspecific esterase positive, but peroxidase negative. The surface marker profile shows that the TER‐3 cells are strongly positive for myeloid, lymphoid, and megakaryocytic antigens such as CD15, CD19, and CD61, and negative for some common multilineage antigens such as CD13, CD33, and CD34. Thus, this cell line has a multilineage phenotype, suggesting that the transformation event occurred in multipotent stem cells. Dianisidine‐ and nonspecific esterase‐positive TER‐3 cells increase with granulocyte‐colony stimulating factor (G‐CSF) rather than with IL‐3. These results suggest that the cell line is useful for understanding the mechanism underlying G‐CSF‐associated hematopoietic cell differentiation and activation in the patient with MDS. J. Cell. Physiol. 191: 183–190, 2002.


Oncogene | 1989

Human ret proto-oncogene mapped to chromosome 10q11.2.

Yukihito Ishizaka; Fumio Itoh; Tomoko Tahira; Isuzu Ikeda; Takashi Sugimura; James D. Tucker; Fertitta A; Anthony V. Carrano; Minako Nagao


The Journal of Pathology | 1994

Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin

Takuro Nakamura; Yukihito Ishizaka; Minako Nagao; Mitsuru Hara; Takatoshi Ishikawa


Japanese Journal of Cancer Research | 1989

Presence of aberrant transcripts of ret proto-oncogene in a human papillary thyroid carcinoma cell line.

Yukihito Ishizaka; Fumio Itoh; Tomoko Tahira; Isuzu Ikeda; Tsutomu Ogura; Takashi Sugimura; Minako Nagao


Japanese Journal of Cancer Research | 1990

Expression of ret Proto‐oncogene in Human Neuroblastomas

Minako Nagao; Yukihito Ishizaka; Akira Nakagawara; Kimitoshi Kohno; Michihiko Kuwano; Tomoko Tahira; Fumio Itoh; Isuzu Ikeda; Takashi Sugimura

Collaboration


Dive into the Yukihito Ishizaka's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mari Shimura

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fumio Itoh

Sapporo Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kiyohiko Hatake

Japanese Foundation for Cancer Research

View shared research outputs
Researchain Logo
Decentralizing Knowledge